Life Sciences Archives - Becker's Hospital Review

Can an AI drug slow aging? | Mayo Clinic, Thermo Fisher debut disease detection joint venture | Wegovy cuts child obesity rates | Lung disease drug posts record 56% reduction | 100% of cancer centers report at least 1 drug shortage

Plus: Novo Nordisk secures injunction over Ozempic, Wegovy claims. September 16, 2026 1. Can an AI-generated drug slow aging? 6 notes Full story 2. Mayo Clinic, Thermo Fisher debut disease detection joint venture Full story 3. Reimbursement complexity threatens pharmacy margins.…

Pancreatic cancer drug shrinks tumors in 33% of patients | FDA warns on compounded GLP-1s: 1,700+ reports | FDA OKs 1st-of-its-kind breast cancer drug | Novartis pauses CAR-T trials after 3 deaths | GLP-1 use rising fast among children

Plus: What’s ahead for 13 weight-loss drugs in the pipeline. September 9, 2026 1. FDA warns clinicians on compounded GLP-1s amid 1,700+ safety reports Full story 2. Pancreatic cancer drug shrank tumors for 1 in 3 lung cancer patients: Early…

Pancreatic cancer drug nearly doubles survival time | Mounjaro cleared to reduce cardiovascular risk | GLP-1s and breast cancer: 5 notes | FDA approves 1st-of-its-kind drug for rare blood disorder | Ifosfamide shortage turns critical

Also inside: AstraZeneca halts a lung cancer drug trial. September 2, 2026 1. FDA approves pancreatic cancer drug that nearly doubles survival time Full story 2. FDA expands Mounjaro approval to reduce cardiovascular risk Full story 3. A patient’s financial instability can…

Regenxbio trial paused again after spine masses found | FDA OKs first-line treatments for 3 cancers | Lilly, Novo Nordisk combat GLP-1 copycats | Thyroid drug recalled nationwide | 6 new FDA approved drugs to know

Also inside: which drug categories have the most active shortages right now. August 26, 2026 1. FDA pauses Regenxbio trial again after spine masses found in 5 patients Full story 2. FDA approves new first-line treatments for 3 cancers Full…

FDA rejects rival to Novartis cancer therapy | Prader-Willi drug faces concerns after 7 deaths | How AstraZeneca's $400B deal fell apart | Melanoma vaccine clears phase 3 trial | 8 GLP-1 updates to know

Novartis’ rival gets rejected, AstraZeneca’s deal collapses and a new myeloma drug clears the FDA. August 19, 2026 1. Clinicians flag safety concerns for Prader-Willi drug after 7 deaths Full story 2. FDA rejects cancer therapy positioned to rival Novartis…

Lilly sues over fake obesity drug sales | Moderna's mRNA flu vaccine gets FDA OK | Court sides with Lilly, Novo in GLP-1 antitrust fight | FDA greenlights cholesterol + narcolepsy drugs

Also inside: FDA clears the first drug for narcolepsy Type 1. August 12, 2026 1. Lilly sues 6 companies over alleged retatrutide sales Full story 2. FDA approves Moderna’s mRNA flu vaccine Full story 3. Specialty pharmacy is becoming a…

AstraZeneca weighs $400B Bristol Myers merger | HHS to end 'dangerous' life sciences research funding | GLP-1s enable personalized obesity care | FDA panel backs melanoma therapy | Who wins under CMS' 340B proposal?

A $400B pharma merger, a GLP-1 breakthrough and a fight over 340B — plus HHS’s funding cuts. August 5, 2026 1. AstraZeneca weighs $400B Bristol Myers merger Full story 2. GLP-1 therapies may enable personalized obesity care Full story 3.…

FDA panel: Ease restrictions on 6 peptides | Where the GLP-1 compounding fight stands | FDA OKs 1st Tylenol pain drug | FDA issues 17 peptide guidances | 6 GLP-1 findings to know

Also inside: a nationwide recall on thyroid medication. July 29, 2026 1. FDA panel recommends easing restrictions on 6 of 7 peptides: What to know Full story 2. Where the GLP-1 compounding fight stands: 5 things to know Full story…

The hidden cost of GLP-1s | FDA approves 1st gene-targeting cancer drug | GLP-1 compounders find loophole | New cholesterol guideline adds 21.5M statin candidates | Brand-name drug denials surge

FDA approves gene therapy for cancer, GLP-1 fallout and a new 340B reform push. July 22, 2026 1. FDA approves gene-targeting cancer drug Full story 2. The hidden cost of the GLP-1 boom: 5 notes Full story 3. How CFOs…

FDA approves 1st on-body cancer drug | What to know about the peptide boom | Cyclospora outbreak surpasses 2,600 cases | 6 things to know as GLP-1 use hits record high | Novo eyes GLP-1 implant as next bet

Plus: a wearable drug approval, a fast-moving outbreak and the latest in the obesity drug race. July 15, 2026 1. FDA approves 1st on-body cancer drug Full story 2. The peptide boom: What healthcare leaders should know Full story 3.…

Join the 500,000+ healthcare executives who start their day with Becker's